UA126979U -
METHOD FOR PHARMACOLOGICAL CORRECTION OF DISORDERS OF CENTRAL NERVOUS Cognitive Functions AND PSYCHOEMOTIONAL SPHERE AFTER KETHAMIN ANESTHESIS
- Google Patents
METHOD FOR PHARMACOLOGICAL CORRECTION OF DISORDERS OF CENTRAL NERVOUS Cognitive Functions AND PSYCHOEMOTIONAL SPHERE AFTER KETHAMIN ANESTHESIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Запорізький Державний Медичний УніверситетfiledCriticalЗапорізький Державний Медичний Університет
Priority to UAU201801588UpriorityCriticalpatent/UA126979U/en
Publication of UA126979UpublicationCriticalpatent/UA126979U/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicinal Preparation
(AREA)
Abstract
Спосіб фармакологічної корекції порушень когнітивних функцій центральної нервової системи і психоемоційної сфери після кетамінової анестезії в експерименті включає застосування лікарського засобу. Лабораторним тваринам інтраназально протягом 3 діб вводять ноопепт у дозі 10 мг/кг та цереброкурин у дозі 200 мкл/кг один раз на добу, при цьому використовують лікарську форму гель.A method of pharmacological correction of disorders of the cognitive functions of the central nervous system and the psycho-emotional sphere after ketamine anesthesia in the experiment involves the use of a drug. Laboratory animals were administered intranasally for 3 days with noopept at a dose of 10 mg / kg and cerebrocurine at a dose of 200 μl / kg once daily using a gel dosage form.
UAU201801588U2018-02-192018-02-19
METHOD FOR PHARMACOLOGICAL CORRECTION OF DISORDERS OF CENTRAL NERVOUS Cognitive Functions AND PSYCHOEMOTIONAL SPHERE AFTER KETHAMIN ANESTHESIS
UA126979U
(en)
methods and compositions using 4-amino-2- (2,6-dioxo-piperidin-3-yl) -isoindoline-1,3-dione for treatment and management of central nervous system cancers
methods for treating or preventing a central nervous system disorder, for controlling a central nervous system disorder and for reducing or preventing an adverse effect associated with the administration of a secondary active ingredient in a patient suffering from a central nervous system disorder, and pharmaceutical composition